Skip to main content
Ingrid Vanderelst Toronto Lawyer

Ingrid E. VanderElst, PhD *

Partner | Trademark Agent Fasken
The Life Sciences Industry is highly regulated.
Jurisdiction Ontario, 2000
Language(s) English, Italian
Office(s) Toronto
Contact
*practising through a professional corporation
Share
  • LinkedIn

Overview

Ingrid VanderElst is co-chair of the Ontario region’s Life Sciences group. Regularly assisting clients in the health products and related service industries, Ingrid advises on regulatory and intellectual property issues. Clients include pharmaceutical, natural health product, medical device, cosmetic and food manufacturers, as well as pharmacy and laboratory services providers and agri-business operators.

On the regulatory side, Ingrid has assisted clients with product licensing, establishment licensing, manufacturing requirements (including GMP compliance), packaging and labeling reviews, as well as advised on advertising, marketing and distribution, product recalls, drug pricing (including PMPRB compliance) and reimbursement issues, including formulary listing.  As regards intellectual property matters, she advises on licensing and transfer of patents and trademarks, patent and trademark prosecution, patent listing under the Patented Medicines (Notice of Compliance) Regulations and data protection, and provides support on the acquisition or disposition of technology assets and intellectual property portfolios.

A significant component of Ingrid’s practice relates to advising clients on privacy related to regulated health products and allied services industries. This includes providing guidance on health privacy issues associated with clinical trials, sponsored research and patient support programs, as well as privacy considerations that arise in connection with commercial operations of pharmacies, laboratories and other health services providers. Ingrid has assisted clients with drafting patient informed consents in the context of clinical trials and patient support programs, drafting privacy policies and consents for patient-facing websites, providing guidance concerning information transfers in connection with corporate transactions and dealing with privacy complaints and privacy breaches, including assessment of reporting obligations. Ingrid also provides advice concerning compliance with Canada’s anti-spam law for companies operating within the regulated health products and related services industries.

Ingrid hold a Ph.D. in genetics. Previous experience in the field includes the development of anti-metastatic chemotherapeutics and the study of gene regulation during oncogenesis.

Ingrid is a registered trade-mark agent.

Achievements

  • Recognized as a Thomson Reuters Stand-out Lawyer, Thomson Reuters stand-out lawyers 2024 to 2026
  • Recognized in the Canadian Legal Lexpert Directory in Life Sciences & Health, Lexpert 2022 to 2026
  • Recognized in Biotechnology Law and Life Sciences Practice and Intellectual Property Law and recognized as Lawyer of the Year (2022) for Biotechnology Law in Toronto, The Best Lawyers in Canada 2019 to 2026
  • Recognized nationwide in Life Sciences: Regulatory/Compliance, Chambers Canada 2017 to 2026
  • Recognized as Recommended in Life Sciences, Lexology Index 2021 to 2025
  • Recognized in the Canadian Legal Lexpert Directory in Biotechnology , Lexpert 2018 to 2021
  • Recognized for Life Sciences, Who's Who Legal Canada 2016 to 2019
  • Recognized for Life Sciences, Who’s Who Legal 100 2014 to 2016
  • Law Business Research's "Leading lawyer" in Life Sciences, Who's Who Legal Canada 2010 to 2015
  • Recognized for Biotechnology , Canadian Legal Lexpert Directory 2014
2016 to 2019 Who's Who Legal Canada Recognized for Life Sciences
2014 to 2016 Who’s Who Legal 100 Recognized for Life Sciences
2010 to 2015 Who's Who Legal Canada Law Business Research's "Leading lawyer" in Life Sciences

Experience

  • Tanabe Pharma Corporation sells global ALS Therapy business rights to Shionogi in a US$2.5 billion strategic transaction, [Deal - Tanabe Pharma Corporation], Japanese pharmaceutical company completes sale of business rights.
  • ATB Securities Inc. leads private placement of senior secured convertible debentures of The Cannabist Company Holdings Inc., [Deal - ATB Securities Inc.], Cultivator, manufacturer and provider of cannabis products and related services, completes private placement offering.
  • Anjac SAS acquires Apollo Healthcare Corp., [Deal - Anjac SAS], Paris-based health and beauty services provider acquires Canadian-based company specializing in the development and production of personal care, OTC and wellness products.
  • Aphria and Tilray complete C$5 billion business combination to create largest global cannabis company, [Deal - Aphria Inc.], All-share acquisition gives rise to the world’s largest global cannabis company based on pro forma revenue
  • Sterling Packers Limited closes its sale to Premium Brands Holdings Corporation, [Deal - Sterling Packers Limited], Canadian leader in food warehousing and storage services acquired by owner of a broad range of specialty food manufacturing and distribution businesses
  • McCain Foods Limited sells a majority stake in Wong Wing Foods, [Deal - McCain Foods Limited], McCain completes its sale of a majority stake in the Wong Wing business unit.
  • Village Farms International Inc. Completes $28.75 Million Bought Deal Offering of Common Shares, [Deal - Beacon Securities Limited and GMP Securities L.P.], On October 22, 2019, Beacon Securities Limited and GMP Securities L.P. co-led a syndicate of underwriters (the “Underwriters”) that conducted a bough-deal short form prospectus supplement offering for Village Farms International Inc. (“Village Farms”). Village Farms offered and sold 3,059,000 com...
  • The Flowr Corporation completes a C$43.5 million equity financing, [Deal - The Flowr Corporation], The Flowr Corporation (the “Company” or “Flowr”) closed a short form prospectus offering of units of the Company (the “Company”). A total of 10,610,000 Units, consisting of one common share and one half of one common share purchase warrant, were issued at a price of C$4.10 per Unit, for aggregate...
  • Kraft Heinz Co’s C$1.62 billion sale of its Canadian natural cheese business to Parmalat SpA, [Deal - Kraft Heinz Canada Inc.], On Tuesday, July 2, 2019 Kraft Heinz Canada Inc. completed the previously announced C$1.62 billion sale of its Canadian natural cheese business to Parmalat Canada Inc. The transaction followed a competitive bidding process, and included the sale of well-known natural cheese brands Cracker Barrel,...

Career & Education

Education

  • LLB Osgoode Hall Law School at York University
  • Ph. D., Genetics
  • MSc, Medical Genetics University of Toronto
  • BSc, gold medallist, Genetics University of Western Ontario

Community involvement

  • Committee member, Animal Care Committee, Toronto Centre for Phenogenomics, (2010-2012)

Memberships & Affiliations

  • Member, Orphan Drug Group, BIOTECanada
  • Member, SEB Task Force, BIOTECanada
  • Member, Canadian Bar Association, Biotechnology Committee
  • Member, American Bar Association, Health Law Section

Knowledge

  • Ontario Moves to Regulate Preferred Pharmacy Networks (PPNs), 11/11/2025
  • At Long Last: The New PMPRB Guidelines Are Here, 7/21/2025
  • Pharma and Device Compliance in Canada 2024 - 2025 Year In Review, 6/5/2025
  • New PMPRB Draft Guidelines Set Out Administrative Process for Excessive Price Hearing Recommendation, 12/30/2024
  • Federal Pharmacare Is Now Law, 10/15/2024
  • A Closer Look at Supplemental Ingredients in Food: New Precision from Health Canada, 10/9/2024
  • Pharma and Device Compliance in Canada 2023 - 2024 Year In Review, 7/30/2024
  • New PMPRB Discussion Guide Sets Out Patented Medicine Price Review Framework, 7/4/2024
  • Federal Pharmacare Bill Proposes Universal Drug Coverage, 3/5/2024
  • Finally! Health Canada’s New Guidance on the Distinction Between Advertising and Other Activities is Now Available, 8/3/2023

Events

  • Artificial Intelligence in Health & Life Sciences, 6/11/2026
  • Drug Pricing in Canada: Navigating Potential U.S. MFN Implications, 2/6/2026
  • LSO Knowledge and Networking Breakfast: Canada’s Moment to Lead – Brain Gain & Talent Access in Canada’s Life Sciences Sector, 6/5/2025
  • LSO Knowledge and Networking Breakfast: Member Marathon Breakfast, 5/20/2025
  • LSO Knowledge and Networking Breakfast, 2/12/2025
  • Pharmaceutical Advertising - The NEW Distinction Policy, 9/15/2023
  • Do’s and Don’ts of Buying and Selling your IP Assets, 11/18/2016
  • 'Back to School' Pharma Forum 2015, 9/24/2015
  • "Back to School" Pharma Forum, 9/18/2014
  • Labelling and Marketing Natural Health Products in Canada: Regulatory Issues and Class Actions, 11/28/2013

News

  • Fasken Will Be at the Pharma & MedTech Compliance Conference in Toronto, 5/25/2026
  • Fasken’s Christine Elliott a Featured Guest at Life Sciences Ontario’s Ideas to Action Forum, 9/17/2025
  • Fasken will be at the Pharma & MedTech Compliance Conference in Toronto, 4/30/2025
  • Fasken Wins “Workers' Compensation Law Firm of the Year” and “Mining Law Firm of the Year” in the 2022 Best Lawyers in Canada Guide, 8/26/2021
  • Droit-inc mentions 13 lawyers from the firm in an article on an important transaction, 11/8/2018
  • Fasken Wins Labour and Employment Law Firm of the Year in the 2019 Best Lawyers in Canada Guide, 8/21/2018
  • The 2018 Canadian Legal Lexpert Directory recognizes 200 Fasken lawyers, 4/12/2018
  • Who’s Who Legal: Canada 2016: 68 Fasken Martineau lawyers ranked, 11/4/2016
  • Awards and Top Recognition for Fasken Martineau’s Life Sciences Group by Industry Peers, 10/4/2016
  • Chambers Canada 2017 Guide recognizes 83 Fasken Martineau lawyers and names us “Employment Law Firm of the Year”, 10/3/2016

Publications

  • Health Canada is cracking the whip on advertising violations, 2/26/2016
  • Draft Update to Intellectual Property Enforcement Guidelines, 6/9/2015
  • Innovation Under Siege: Definition of Innovative Drug Narrowed for Purposes of Data Protection, 8/1/2013
  • Canada to Change the Regulation of "Food-Like" Natural Health Products, 6/1/2012
  • Canada Consumer Product Safety Act Aims to Strengthen Product Safety Laws, 6/1/2011
  • Canadian Parliament Proposes PIPEDA Amendments, Anti-Spam Law, 6/1/2010
  • Enhanced Protection for Licensees of Intellectual Property in the Event of Licensor Bankruptcy, 2/1/2010
  • Proposed Amendments to the Patented Medicines, 6/2/2008
  • Confusion in Drug and Health Product Names: Health Canada's New "Look-Alike, Sound-Alike" Policy, 8/1/2006
  • New Rules for Labeling and Importation of Cosmetics in Canada, 11/30/2005
Article Health Canada is cracking the whip on advertising violations Inside Internal Controls
Article Draft Update to Intellectual Property Enforcement Guidelines Competition Chronicle
Book Innovation Under Siege: Definition of Innovative Drug Narrowed for Purposes of Data Protection Life Sciences Bulletin

Speaking Engagements

  • Do’s and Don’ts of Buying and Selling your IP Assets, 11/18/2016
  • Quebec Best-Available-Price (“BAP”) policy, post Bill 28, 8/31/2015
  • Orphan Drugs: Legal Perspectives, 6/23/2015
  • The Latest Developments with Orphan Drugs and New Drug Therapies: Is a New Model Required, 4/1/2015
  • Food Fights - The Intersection Between Food Regulation and Food Litigation, 10/21/2013
  • Crowd Sourcing – the Ultimate Collaboration, 6/20/2013
  • IP Update: Ensuring Ample Proprietary Rights are Imposed on Your Organization's Valuable Creative Works, 1/22/2010
  • The Merck v. Integra Decision and its Impact on Research and Licensing Agreements, 10/3/2005
Do’s and Don’ts of Buying and Selling your IP Assets location location Toronto
Orphan Drugs: Legal Perspectives Health Canada Regulatory Reforms Summit, Strategy Institute